BioPharma Dive January 14, 2025
Jonathan Gardner

The company said it overestimated demand of its obesity and diabetes drugs, which brought in $5.4 billion during the fourth quarter.

Dive Brief:

  • Eli Lilly on Tuesday said the company’s revenue in 2024 totaled about $45 billion, a 32% jump on 2023’s total but less than what it had estimated in October.
  • Third quarter sales of Mounjaro and Zepbound, its GLP-1 drugs for diabetes and obesity, were below Wall Street analysts’ expectations at $3.5 billion and $1.9 billion, respectively. CEO David Ricks said GLP-1 market growth was slower than the company anticipated.
  • Shares of the Indianapolis-based company fell by as much as 8% in morning trading, shaving tens of billions of dollars from its market valuation. Since hitting a...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Pharma / Biotech
Related Articles:
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected
NIH's unfinished business
AbbVie to write off $3.5B over failed schizophrenia drug
Drug Price Negotiation Requires Oversight To Protect Older Americans

Share This Article